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Abstract
The exploitation of silver nanoparticles (AgNPs) in biomedicine represents more than one third of their overall application. Despite
their wide use and significant amount of scientific data on their effects on biological systems, detailed insight into their in vivo fate
is still lacking. This study aimed to elucidate the biotransformation patterns of AgNPs following oral administration. Colloidal
stability, biochemical transformation, dissolution, and degradation behaviour of different types of AgNPs were evaluated in systems
modelled to represent biological environments relevant for oral administration, as well as in cell culture media and tissue compart-
ments obtained from animal models. A multimethod approach was employed by implementing light scattering (dynamic and elec-
trophoretic) techniques, spectroscopy (UV–vis, atomic absorption, nuclear magnetic resonance) and transmission electron micros-
copy. The obtained results demonstrated that AgNPs may transform very quickly during their journey through different biological
conditions. They are able to degrade to an ionic form and again reconstruct to a nanoparticulate form, depending on the biological
environment determined by specific body compartments. As suggested for other inorganic nanoparticles by other research groups,
AgNPs fail to preserve their specific integrity in in vivo settings.
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Introduction
The global consumption of silver nanoparticles (AgNPs)
has been steadily increasing in the last decade and estimated
to reach over 200 tons/year by 2022 [1]. AgNPs are
extensively used in multiple industries and fields spanning
from electronics, textiles, food, cosmetics to water treatment
and healthcare [2,3]. A significant market contribution
originates from the agriculture sector as evidenced by the
Center for Food Safety, which listed more than 100 AgNP-
containing food products [4]. The biomedical use of AgNPs
represents the largest proportion of the market share [1]
encompassing antimicrobial coatings on medical devices
(catheters, stents, implants), wound dressings, targeted drug
delivery, cancer therapy and diagnostics (biosensing, bio-
imaging) [2,3]. Such prevalence has raised concerns among
the regulatory authorities about the safety of AgNPs for
humans due to significant lack of relevant regulatory data.
Thus, the Scientific Committee on Consumer Safety (SCCS)
highlighted in its final Opinion on Colloidal Silver (nano) that
insufficient data on AgNP physicochemical properties and
toxicology in cosmetics hinder the health hazards caused by
AgNPs [5]. Earlier, the Scientific Committee on Emerging
and Newly Identified Health Risks (SCENIHR) raised ques-
tions on how different forms of Ag used in consumer and
medical products may be related to human exposure and safety
as AgNPs may undergo complex transformations in biological
media [6].
It is well known that AgNP physicochemical characteristics,
such as size, shape, surface charge, surface functionalization, or
core composition determine their interactions with biological
structures and affect their uptake, toxicokinetics, and toxicody-
namics [7-14]. Therefore, any change in those properties will
have consequences on the biological fate of AgNPs. No matter
how well the properties of pristine AgNPs were tuned during
production they will not be retained in biological media [9-14].
In biological media, AgNPs may be transformed into different
forms by aggregation, agglomeration, dissolution, interaction
with biomolecules, or generation of reactive oxygen species
(ROS) that may lead to the coexistence of nanoparticulate,
ionic, metallic, and complex salts forms [9-14]. Despite many
scientific and medical evidences for (bio)chemical transformat-
ion patterns of AgNPs [15], questions about their final fate in
the body are still open. Irreversible skin discoloration or argyria
was described in patients that were overexposed to Ag via dif-
ferent routes [16-20]. In these patients, Ag granules were
detected in the connective tissue of the dermis [18,20]. In fact,
some Ag-containing drugs were retracted from clinical use due
to the observed generalized argyria after long-term use or drug
abuse [21]. Animal experiments demonstrated Ag accumula-
tion in the liver, kidneys, brain, and testis after oral exposure to
AgNPs; however, the chemical form of Ag remained undefined
in these cases [22].
In media of high ionic strength and low pH the AgNPs aggre-
gate and/or dissolve [23]. Under such conditions, the repulsive
electrostatic forces between particles with the same surface
charge are weakened, leading to aggregation upon collision
[10]. The AgNPs with bulky coatings are less sensitive to this,
since their stabilisation is steric and not electrostatic [14]. The
dissolution of AgNPs is an oxidative process aided by protons
[9,24,25] through which AgNPs release ions from the surface.
The dissolution occurs faster for smaller NPs (larger surface
area) and in the presence of molecules that may complex the
ions [14]. Ag+ released into complex media is highly reactive
and tends to associate with both organic and inorganic ions.
With chlorides and sulphides, it forms AgCl and Ag2S, respec-
tively, that are poorly soluble and precipitate into granules simi-
lar to aggregates [9,10,23,24]. The evaluation of AgNP
biotransformation under in vitro settings revealed that argyrial
deposits are created by several pathways, including partial
AgNPs dissolution in the gastric fluid, uptake and systemic
transport of ionic and nanoparticulate Ag as thiol and selenium
complexes, and final deposition in the near-skin regions [15].
Especially important is the process of interaction with thiols
owing to their many physiological roles and evidences for thiol-
containing proteins as major targets for toxic effects of ionic Ag
[25]. In the presence of biothiols the soluble complexes are
formed. Thiols possess a high affinity for soft Lewis acid metals
and may easily coordinate Ag+ [9,26,27]. The association of Ag
with sulphur and the formation of Ag2S granules from ion
exchange or Ag–thiol complexes is known as sulphidation
[28,29].
However, many other scenarios should be considered during an
in vivo journey of AgNPs and Ag+ ions, especially their interac-
tions with biomolecules, such as lipids, metabolites, sugars, and
proteins that will be adsorbed onto the nanoscale surface and
spontaneously form biomolecular corona [9,11,25]. Corona
generally protects from both aggregation and dissolution even
though some high-affinity molecules might aid dissolution by
pulling ions away from the surface [9,30].
Upon oral administration, AgNPs are first exposed to saliva and
then to gastric fluid. These two media are characterized by dif-
ferent pH values, ranging from 6.2 to 7.6 in saliva or from 1.5
to 3.5 in gastric fluid, which may significantly affect AgNP
dissolution. Moreover, the lining oral mucosa may significantly
affect AgNPs and determine their colloidal stability and cellu-
lar interactions as evidenced earlier [27,31-33]. In the acidic
medium of the stomach, AgNPs both agglomerate and dissolve
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Table 1: Information on the composition and pH of biologically relevant artificial media used for the evaluation of the stability and transformation of
AgNPs.
abbreviation medium pH composition
CCM high glucose Dulbecco’s modified Eaglemedium (DMEM) 7.2
commercial (containing 4500 mg/L glucose,
sodium pyruvate, and sodium bicarbonate, without
ʟ-glutamine)
m(CCM+BSA) DMEM + 10% bovine serum albumin (BSA) 7.2
commercial (containing 4500 mg/L glucose,
sodium pyruvate, and sodium bicarbonate, without
ʟ-glutamine)
mCYS cysteine solution 5.3 100 mg/L cysteine
m(CYS+BSA) cysteine solution with BSA 6.4 100 mg/L cysteine + 500 mg/L BSA
mGSH glutathione solution 3.2 100 mg/L glutathione
m(GSH+BSA) glutathione solution with BSA 4.7 100 mg/L glutathione + 500 mg/L BSA
ALF artificial lysosomal fluid 4.5
NaCl (3.210 g/L), NaOH (6.000 g/L), citric acid
(20.800 g/L), CaCl2 (0.097 g/L), NaH2PO4∙7H2O
(0.179 g/L), Na2SO4 (0.039 g/L), MgCl2∙H2O
(0.106 g/L), glycerol (0.059 g/L), sodium citrate
dihydrate (0.077 g/L), sodium tartrate dihydrate
(0.090 g/L), sodium lactate (0.085 g/L), sodium
pyruvate (0.086 g/L), formaldehyde (1.000 mL/L)
AGF artificial gastric fluid 2.0 NaCl (34.2 mM), pepsin (0.1 g/L), HCl q.s. pH 2
PBS phosphate buffer saline 7.4 KH2PO4 (0.144 g/L), Na2HPO4∙7H2O (0.795 g/L),NaCl (9 g/L)
[15,26,34]. The transformation will likely be incomplete due to
protein corona formation and short residence time [9,15,26]. In
the intestinal environment, a higher pH may slow down the loss
of AgNPs [10]. Indeed, there is even evidence of agglomerates
breaking down and releasing original AgNPs [32]. In both envi-
ronments, the dissolved Ag may be released and may interact
with many molecules. Although the majority of Ag will be
cleared from the body through faeces [35], released Ag+ and its
soluble complexes will be absorbed through passive or active
transport [26]. It was also proposed that the AgNPs pass
through the intestinal barrier [36,37]. Absorbed Ag will then
interact with tissues and cells, being internalized through
phagocytosis or pinocytosis and metabolised in lysosomes
[11,26]. AgNPs will again dissolve in lysosomes due to their
low pH and may be then released into the cytosol [38].
In short, the fate of AgNPs in the human body is extremely
complex; however, many chemical pathways have not yet been
systematically investigated and remain unclear. Here we aimed
to examine the biotransformation of differently coated AgNPs
[39] simulating real body conditions after oral uptake. The
systematic work presented here addresses not only the evolu-
tion of various types of AgNPs in different media and tissue
extracts, but also demonstrates how different AgNPs may be
affected in biological media in a short time leading to the for-
mation of new types of materials in different tissues. The reduc-
tion and de novo synthesis of AgNPs in different biological
matrices should be considered during a risk assessment of
AgNP-based consumer products.
Results and Discussion
The fate of metallic NPs in the human body is a critical ques-
tion for assessing their safety and efficacy when used in differ-
ent medical or consumer products. Due to technical limitations
and, more importantly, ethical constraints, it is usually not
possible to track NPs in human tissues, which demands the
implementation of biological model systems either in vitro or in
vivo. This study was motivated by an interesting observation
that emerged already during our previous research on acute
effects of AgNPs in rodents [40]. Here, we exposed Wistar rats
to poly(vinylpyrrolidone) (PVP)-coated AgNPs for 28 days. A
microscopic examination of liver tissues of treated animals
revealed an interesting result (described below) that initiated
our subsequent research (presented here) on a possible transfor-
mation pattern of AgNPs in different biological environments
during their in vivo journey. The colloidal stability, size,
charge, and dissolution behaviour of AgNPs stabilized with
neutral, positively, and negatively charged coating agents were
determined after incubation in artificial media (depicted in
Table 1) as well as in real biological fluids, obtained from
animal experiments. A multimethod approach was used to ex-
amine their behaviour and transformation under experimental
conditions relevant for in vivo settings by performing dynamic
light scattering (DLS), electrophoretic light scattering (ELS),
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Figure 1: TEM images of freshly synthesized silver nanoparticles (AgNPs) coated with PLL, AOT, or PVP dispersed in ultrapure water at a concentra-
tion of 10 mg Ag/L. Scale bars are 100 nm.
Table 2: Values of primary size (obtained by TEM), hydrodynamic diameter (dH), zeta potential (ζ), and percentages of released ionic silver in
colloidal suspension of AgNPs coated with PLL, AOT, or PVP.
nanoparticle primary size (nm) dH (nm) ζ (mV) %Ag+
PLL-AgNP 8.4 ± 4.7 4.6 ± 0.9 (97%),
15.2 ± 5.3 (3%)
44.9 ± 6.5 0.8
PVP-AgNP 9.2 ± 3.6 5.0 ± 1.2 (98%),
31.2 ± 3.5 (2%)
−24.3 ± 3.7 0.6
AOT-AgNP 7.8 ± 4.4 8.5 ± 4.5 (100%) −35.8 ± 6.9 0.4
graphite furnace atomic absorption spectroscopy (GF-AAS),
nuclear magnetic resonance (NMR) spectroscopy, and transmis-
sion electron microscopy (TEM) experiments.
Physicochemical characteristics of freshly
prepared AgNPs
Freshly prepared AgNPs coated with PVP, sodium bis(2-ethyl-
hexyl)sulfosuccinate (AOT), and poly(ʟ-lysine) (PLL) were
dispersed in ultrapure water (UPW) and examined by TEM to
confirm their original morphology. These coating agents were
selected according to their relevance in biomedicine, as they are
the most frequently used stabilization agents for AgNPs accord-
ing to the Web of Science database [41]. Moreover, they cover
neutral, positive, and negative charge. All three AgNPs were
found to be spherical, with a primary size below 10 nm
(Figure 1). They were further examined by DLS and ELS
(Table 2). The hydrodynamic diameter (dH) of all three AgNPs
was below 10 nm, matching the primary size, with a small per-
centage of 20 nm particles in the case of AOT- and PVP-coated
AgNPs. The major difference between different AgNPs was
their potential values ζ, which were consistent with the charges
of coating molecules used for their decoration. The ζ potential
of AOT-AgNPs was strongly negative (−35.8 ± 6.9 mV), while
for PLL-AgNPs it was strongly positive (+44.9 ± 1.4 mV).
As a consequence, both AgNPs exhibited a long-term (over
2 months) stability in UPW due to electrostatic repulsive forces.
Indeed, the NPs are considered electrostatically stabilised if
their ζ potential is above +30 mV or below −30 mV [42]. How-
ever, PVP-AgNPs were weakly negatively charged, even
though PVP is a neutral polymer. The reason behind this can
be found in residual BH4− ions that became strongly attached
to the surface during the synthetic process and could not
be removed by purification. Despite the ζ potential of
−24.3 ± 3.7 mV, PVP provided good colloidal stability through
steric stabilisation.
The amount of free Ag+ ions in AgNPs dispersed in UPW at a
concentration of 10 mg Ag/L was determined to be below 1%
for all the three cases, confirming the coating protection against
dissolution.
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Figure 2: TEM images of liver obtained from (a) untreated and (b) treated healthy male Wistar rats. The rats were treated orally with a daily dose of
1 mg Ag/kg of body weight of PVP-coated AgNPs during 28 days.
Experiments with animal tissues
In animal experiments, PVP-coated AgNPs were given orally to
three-month old male Wistar rats of 320–350 g of body weight
(b.w.) at a daily dose of 1 mg Ag/kg b.w. After 28 days of expo-
sure, the rats were sacrificed under general anaesthesia and
tissues were collected for further analysis. This may be regarded
as an extension of our previous work [40]. In addition, liver
tissues of control (untreated) and treated animals were prepared
for TEM analysis, which revealed quite surprising observations.
While TEM images obtained for control animals conformed to
classical histological features of liver tissue (Figure 2a), large
electron-dense spherical and cubic forms were found in the liver
slices of treated animals (Figure 2b).
Our first explanation for the origin of these forms was the prep-
aration of the tissue samples for TEM examination (i.e., precipi-
tates of Pb acetate or OsO4). However, such electron-dense
cubic or spherical structures were not found in the liver of
control animals, meaning that they originate from the accumula-
tion and biotransformation of AgNPs. Indeed, Prucek et al. [43]
reported rapid crystallization of primary AgNPs to a one-order
larger crystals in NaCl-rich media, in which a high concentra-
tion of chloride ions catalyse a controlled recrystallization of
AgNPs. They observed structures similar to the forms presented
in Figure 2b. As these large cubic and ball-like structures were
not located inside hepatocytes, but extracellularly, we con-
cluded that the crystallization of PVP-AgNPs, as observed in
Figure 2b, occurred already in the circulation as blood repre-
sents a chloride-rich medium. To gain more detailed insight into
the biotransformation of AgNPs, differently coated AgNPs were
incubated for 30 min at a concentration of 100 mg Ag/L in PBS,
whole blood (WB), blood plasma (BP), or in 1% (w/v) liver,
brain, and kidney homogenates. In most tissue homogenates,
AgNPs were well dispersed as shown in Figure 3. Although
some aggregates were also visible under these conditions, there
were no large crystals in kidney, liver, or brain homogenates as
observed in vivo (Figure 2). However, the formation of large
crystals was observed after incubation of AgNPs in PBS or BP
(Figure 4). These crystal objects, with sizes in the μm range,
were totally destructed after electron radiation in TEM
(Figure 4c), similar to those observed by Prucek et al. [43].
Nanoscale objects found in PBS and BP incubated with differ-
ent AgNPs (Figure 4) may, thus, be an indirect evidence of
AgCl crystal formation in PBS and BP, which is possible only if
the ionic Ag form is released form the AgNP surface by an oxi-
dative etching process. Such release may be accelerated in the
presence of complexing agents [44,45]. Henglein et al. [46] sug-
gested the mechanism of coordination of Ag+ on the nanoscale
surface by halide ions in media where halide ions are present at
a high concentration. Formed AgCl2− complex ions then
undergo recrystallization into large objects similar to those ob-
served in PBS and BP media. We tried to quantify the release of
Ag+ from the surface of different AgNPs incubated in WB or
tissue homogenates. However, all the attempts to extract free
Ag+ ions from such media by ultracentrifuge filtration failed.
Probably, free Ag+ ions were either bound to biomolecules or
embedded in crystals that were unable to pass through 3 kDa
pores of ultracentrifuge filters (see Experimental section). Due
to these experimental hurdles, we performed an additional eval-
uation of the fate of the ionic Ag form in biological media, such
as WB and tissue homogenates. An examination of the TEM
data revealed quite interesting results. Incubation of AgNO3 in
the liver and brain homogenates led to the formation of small
AgNPs as presented in Figure 4d and Figure 4e, which was con-
firmed by energy-dispersive X-ray spectroscopy (EDX)
(Figure 4f and Figure 4g).
Transformation of different AgNPs in artificial
biological media
In order to gain more coherent insight into the transformation of
different AgNPs in biological media, we examined changes in
their size, surface charge, and dissolution in simpler media (i.e.,
CCM, m(CCM+BSA), mCYS, m(CYS+BSA), mGSH,
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670
Figure 3: TEM images of differently coated AgNPs incubated for 30 min in 1% (w/v) tissue homogenates at a concentration of 100 mg Ag/L. (a) PVP-
AgNPs (kidney), (b) PVP-AgNPs (liver), (c) PVP-AgNPs (brain), (d) AOT-AgNPs (kidney), (e) AOT-AgNPs (liver), (f) AOT-AgNPs (brain), (g) PLL-
AgNPs (kidney), (h) PLL-AgNPs (liver), (i) PLL-AgNPs (brain). Scale bars are 100 nm.
m(GSH+BSA), ALF, and AGF, see Table 1) after 0, 1, 4, and
24 h of incubation. The media AGF, ALF, and CCM can be
used to evaluate the AgNP transformation during their passage
from the gastrointestinal system into the body, after entering the
extracellular matrix and going through cellular uptake. Further-
more, the behaviour of AgNPs was studied in the presence of
the most relevant biothiols: cysteine (CYS) and glutathione
(GSH). Data on the size distribution of different AgNPs in the
tested media are given in Figure 5 and in Supporting Informa-
tion File 1, Table S1, while observed ζ potentials are presented
in Figure 6 and in Supporting Information File 1, Table S2. Al-
though differences in the agglomeration behaviour among dif-
ferent AgNPs were observed depending on the dispersion
media, an increase in agglomeration was generally observed in
media with a higher ionic strength (CCM, mCYS, mGSH, ALF,
and AGF, see Table 1). Such behaviour can be attributed to the
loss of electrostatic repulsion between particles due to the com-
plexation with counter ions present in media with high ionic
strength [8,47]. The presence of proteins prevented AgNP
a g g l o m e r a t i o n  i n  m ( C C M + B S A ) ,  m ( C Y S + B S A ) ,
m(GSH+BSA) due to the formation of protein corona on the
surface of AgNPs even in media with a high ionic strength and
low pH [8,48,49]. The ELS measurements (Figure 6 and Sup-
porting Information File 1, Table S2) confirmed this as all
AgNPs in the presence of BSA were characterized by a ζ poten-
tial close to the value observed for BSA (−7.6 mV). In CCM
with and without the addition of BSA as well as in
m(GSH+BSA), all AgNPs showed the same behaviour. Nega-
tively charged AgNPs (AOT- and PVP-coated) agglomerated
less in CYS-containing media than positively charged PLL-
AgNPs, while an opposite trend was observed in the mGSH me-
dium. This was likely a result of other mechanisms, possibly a
direct interaction of CYS and PLL or due to a well-established
cross-linking property of CYS [50,51]. This effect appeared to
be so strong that it counteracted the stabilising power of BSA
for PLL-AgNPs in m(CYS+BSA).
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Figure 4: TEM images of objects observed after 30 min of incubation of AgNPs or Ag+ in different test media at a concentration of 100 mg Ag/L.
(a) PLL-AgNPs in 1% (w/v) of blood plasma, (b) PLL-AgNPs in PBS, (c) electron-beam-induced transformation of cubic nanocrystals formed after
incubation of AgNPs in PBS, (d) AgNPs formed after Ag+ incubation in 1% (w/v) of liver homogenate, (e) AgNPs formed after Ag+ incubation in
1% (w/v) of brain homogenate, (f) HAADF images of AgNPs formed after incubation of Ag+ in brain homogenate, (g) EDX analysis of nanoscale
objects found in brain homogenates after incubation with AgNO3.
The DLS results indicated that mGSH did not induce a signifi-
cant agglomeration of PLL-AgNPs (Figure 5) probably due to
the supportive complexation of negatively charged GSH to the
positively charged PLL, which was evident at a much lower ζ
potential value of PLL-AgNPs in mGSH (Figure 6) compared
to UPW (Table 2). Obviously, the complexation power of GSH
was decreased in the case of PVP and AOT coating agents due
to either unfavourable steric or electrostatic interactions, respec-
tively. In both ALF and AGF, a significant agglomeration
occurred for all three types of AgNPs. Moreover, a significant
precipitation, visible in the test vials already after 1 h, prevented
the DLS instrument to measure large agglomerates of PVP-
AgNPs in ALF and AGF as well as that of PLL-AgNPs in AGF.
The colloidal instability of all tested AgNPs was also evi-
denced by a significant decrease in the absolute value of their ζ
potential in acidic AGF and ALF media (Figure 6). The precipi-
tates observed in AGF and ALF media, both rich in chloride
ions, probably originate from AgCl that can be formed from re-
leased Ag+ after the stripping of coating agents from the nano-
scale surface which is prone to dissolution [10]. However, the
speciation of Ag forms in biological systems is highly intricate
as the formation of a wide range of Ag complexes is possible
including those with biothiols and chloride [25].
The fate of released Ag+ in the presence of
GSH
In almost all tested media, the degradation of AgNPs leading to
the release of free Ag+ ions was assumed. Indeed, any interac-
tion between the nanoscale surface with complexing agents,
such as biothiols, the dispersion of AgNPs into acidic or chlo-
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Figure 5: Changes in the hydrodynamic diameter (dH) of (a) AOT-
AgNPs, (b) PVP-AgNPs, and (c) PLL-AgNPs in different biological
media after 24 h of incubation. The media abbreviations are explained
in Table 1. The existence of two or three peaks indicates a bimodal or
trimodal size distribution, respectively, with the volume percentage
given next to each point.
ride-rich media, oxidative actions on the nanoscale surface
mediated by ROS or catalysed by biomolecules may lead to
Ag+ release [25]. Moreover, AgNP degradation and dissolution
may occur after oral intake in different biological compart-
ments including gastric and lysosomal fluid. The dissolution of
tested AgNPs in different artificial biological media was evalu-
ated by ultracentrifugation combined with GF-AAS. The disso-
Figure 6: Changes in the ζ potential (in mV) of AOT-AgNPs, PVP-
AgNPs, and PLL-AgNPs in different artificial biological media after 24 h
of incubation. The media abbreviations are explained in Table 1.
lution data (given in Supporting Information File 1, Table S3)
revealed that the released Ag+ fraction did not exceed 3% (w/v)
of total Ag content. These results cannot be taken as evidence of
AgNP stability and they do not necessarily contradict previous
findings. All artificial media contain substances which can pre-
cipitate Ag+, either in the form of complexes similar to those
with CYS and GSH or as insoluble salts, such as AgCl. Such
precipitates cannot pass through the filter used here to separate
free Ag+ ions, leading to the false negative reading of released
Ag fraction. Moreover, CYS or GSH may reduce Ag+ ions back
into AgNPs [15].
The de novo formation of AgNPs from primary particles or
AgNO3 was shown in cellular fractions [52]. Also, biogenic
synthesis was noted in bacterial cells and in many other organ-
isms. It stands to reason that human intracellular or extracel-
lular environments can provide similar conditions [53,54]. Sec-
ondary particles are often found to contain Ag, S, and Cl [34].
Indeed, evidences on the formation of small AgNPs after only
30 min of incubation of AgNO3 in 1% (w/v) brain and liver
homogenates is presented above (see Figure 4f and Figure 4g).
In addition, we tested such scenario by dissolving AgNO3 into
mCYS and mGSH media. Similar to tissue homogenates, small
AgNPs were again found by TEM examination (Figure 7). The
elemental mapping of newly formed particles was done via
EDX. The EDX spectra (Figure 7c) showed Ag, S, Na, C, O,
and Cu. The signals corresponding to C, O, and Cu resulted
from the carbon copper grid, while the Ag signal evidenced that
the captured particles were generated from AgNPs by the reduc-
tive power of CYS (Figure 7a) or GSH (Figure 7b).
Finally, the fate of GSH during the formation of AgNPs was
monitored by 1H NMR spectroscopy (Figure 8). The reaction
Beilstein J. Nanotechnol. 2021, 12, 665–679.
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Figure 7: HAADF–STEM images of the newly formed AgNPs in (a) mCYS and (b) mGSH media. The media abbreviations are explained in Table 1.
The areas identified by red rectangles represent areas examined by EDX. The corresponding EDX spectra are given next to the respective
HAADF–STEM images.
Figure 8: 1H NMR spectra of (a) GSH-coated AgNPs formed during the interaction between AgNO3 and GSH and (b) free GSH. Both spectra are ob-
tained in 25 mM phosphate buffer (pH 6.8). The structure of reduced GSH is shown above panel (a).
was conducted in 25 mM of PB to maintain the pH close to
neutral, since the synthesis does not progress in water due to the
acidic nature of GSH.
The 1H NMR spectrum of 10 mM GSH in PB was recorded
(Figure 8b). It showed four distinct peaks corresponding to
protons bound to carbon at positions nine (overlapped with
Beilstein J. Nanotechnol. 2021, 12, 665–679.
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Figure 9: Biotransformation patterns of AgNPs in biological media.
two), seven, four, and three. The proton at position six over-
lapped with the solvent signal and thus is not shown. The peaks
were assigned according to AIST Spectral Database for Organic
Compounds [55]. Then, a 5 mM solution of AgNO3 was added
and the mixture was left to react for 2 h. During that time, the
solution became opaque and changed colour to brownish-grey
indicating the formation of small AgNPs. Afterwards, the NMR
spectrum was recorded again (Figure 8a). All peaks shifted
downfield by 0.5 ppm, and the peak seven split into two, which
indicates that some interaction was happening through the thiol
group (also bound to C7).
This possibly implies the formation of oxidised glutathione
(GSSG), as noted in our previous work [56]. The most signifi-
cant changes observed were the broadening of the peaks and
loss of resolution, both of which are known signs of ligand
binding to the NP surface [57-59]. Therefore, the spectral evi-
dence points to the generation of AgNPs with GSH as both the
reducing and coating agent, which likely binds to the surface in
its oxidised form. Similarly, Ag cluster nucleation finally
leading to AgNP formation was observed also for the interac-
tion of Ag+ with CYS [60]. Similar to our previous NMR obser-
vation on the CYS oxidation to cystine during Ag cluster nucle-
ation [60], the experiments presented here also indicate the
conversion of GSH to GSSG during the nucleation of Ag clus-
ters with subsequent AgNP synthesis.
Conclusion
The evaluation of NP behaviour in biological media is a crucial
step toward safe biomedical applications. The biotransforma-
tion of AgNPs in the human body results in loss of integrity of
AgNPs. Changes in AgNPs include aggregation, dissolution,
and degradation which lead to the de novo formation of crys-
tals in different tissues (Figure 9). Initially, primary AgNPs
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enter the body where they gain a protein corona, aggregate, and
dissolve to Ag+. Ionic silver may precipitate in the anion-rich
environment of different tissues, where Ag binds to S, resulting
in nanocrystals. Aggregation and corona–NP destabilisation can
also lead to precipitation. Whole blood, liver, and kidney are
glutathione-rich environments, where GSH serves as an in vivo
reducing agent for Ag+ converting it into secondary particles.
In simple biological media, an increase in the agglomeration of
different AgNPs was generally observed with an increase in
ionic strength due to the complexation of particles with counter
ions present in media and loss of electrostatic repulsion be-
tween particles. However, the formation of protein corona
prevented such agglomeration even in media with high ionic
strength and low pH. Negatively charged AgNPs agglomerated
less in CYS-containing media compared to positively charged
PLL-AgNPs possibly due to the cross-linking property of CYS.
Negatively charged GSH interacted with positively charged
PLL-AgNPs leading to their agglomeration, while the GSH
complexation power was decreased for PVP- and AOT-coated
AgNPs due to unfavourable steric or electrostatic interactions,
respectively. In most tissue homogenates, AgNPs were well
dispersed; however, the crystallization of AgNPs was observed
in chloride-rich media resulting in the formation of large cubic
and ball-like crystals as an indirect evidence of the formation of
AgCl crystals and oxidative etching process of AgNPs. The ref-
ormation of AgNPs from primary particles or released Ag+ was
evidenced by the incubation of AgNO3 in liver and brain
homogenates which led to the formation of small AgNPs. More-
over, NMR experiments demonstrated the crucial role of bioth-
iols in this reformation process.
Our results demonstrated that the transformation pathway after
the exposure of AgNPs to biological environments is highly de-
pendent on the properties of the media, including ionic strength
and the presence of proteins. These findings contribute to the
understanding of the in vivo fate of AgNPs and the possible
toxic effects following the biomedical applications.
Experimental
Chemicals
All chemicals were purchased from Merck (Darmstadt,
Germany) unless otherwise specified. Ultrapure water (UPW),
characterized with conductivity of 18.2 MΩ·cm, was obtained
from a GenPure UltraPure water system (GenPure UV, TKA
Wasseraufbereitungssysteme GmbH, Niederelbert, Germany).
Synthesis and characterization of AgNPs
stabilized with different coating agents
AgNPs were synthesised by the reduction of silver nitrate with
sodium borohydride in the presence of AOT, PVP, and PLL as
coating agents to provide colloidal stability to different AgNPs.
The detailed procedure was described previously [39]. The final
concentrations of the reagents in the reaction mixture were 0.5,
0.075, and 0.02 mM for AOT, PVP, PLL, respectively, while
AgNO3 and NaBH4 were added to the final concentration of 2.3
and 5 mM, respectively.
The synthesis of AgNPs in the presence of GSH was performed
by mixing appropriate amounts of AgNO3 and GSH to the final
concentrations of 20 and 10 mM, respectively, in 25 mM of
phosphate buffer solution (K2HPO4/KH2PO4, 0.401:0.014, w/w
[g]). The reaction mixture was left to react for 2 h at room tem-
perature, under constant stirring. The final pH of the reaction
mixture was 6.8.
After synthesis, the AgNP suspensions were centrifuged twice
at 15,000g for 40 min, resuspended in UPW and kept in the
dark at 4 °C. The concentration of Ag in AgNP suspensions was
determined by GFAAS (Perkin Elmer AAnalyst 600, Perkin
Elmer, Shelton, USA). The silver standard solution (1000 mg/L
in 5% HNO3) from Merck (Darmstadt, Germany) was used for
calibration.
All prepared AgNPs were characterized by means of shape, pri-
mary size, size distribution, and surface charge in UPW. The
particle visualization was performed by TEM (902A; Carl Zeiss
Meditec AG, Jena, Germany) operated in bright-field mode
with an acceleration voltage of 80 kV, while a Canon Power-
Shot S50 camera was used to capture the images. The sample
preparation for TEM involved the deposition of a drop of the
AgNP suspension onto a Formvar®-coated copper grid and air-
drying it at room temperature. The TEM images were then used
to measure the primary size (d, nm) of AgNPs for 100 particles
per particle type by using the ImageJ software. The hydrody-
namic diameter (dH) was determined by DLS at 25 °C using
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK)
equipped with a green laser (532 nm) at an angle of 173°. The
values of dH were obtained as the value of the maximum peak
of the size distribution by volume and reported as an average of
ten measurements. The ζ potential values were determined by
ELS using the same Zetasizer Nano ZS instrument. The values
were calculated from the measured electrophoretic mobility and
reported as an average of six measurements. The Zetasizer soft-
ware (6.32; Malvern Instruments, Malvern, UK) was used for
data processing.
Experiments with animal tissues
Three-month-old male Wistar rats, 320–350 g (b.w.) were bred
at the Unit for Laboratory Animals, at the Institute for Medical
Research and Occupational Health, Zagreb, Croatia. The
animals were kept under specific pathogen-free conditions, in
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polycarbonate cages with temperature (23 ± 2 °C) and humidity
(55 ± 7%) control, with a 12 h light/dark reversed cycle. They
were fed standard GLP-certified food (Mucedola, 4RF21, Italy)
and given tap water ad libitum. Healthy rats were randomly
selected and divided into control and treatment groups. The
animals were treated by oral gavage with PVP-AgNPs at a daily
dose of 1 mg Ag/kg b.w. during 28 days, while control animals
were administered with the same amount (0.1 mL) of physio-
logical solution. Despite the applied dose was much higher than
the estimated amount of daily consumption of Ag by humans
through ingestion (i.e. 20–80 µg) [61], the dose of 1 mg Ag/kg
b.w. for animal experiments is 5–50 times lower than the doses
tested in most in vivo studies [40].
After treatment the animals were sacrificed under general
anaesthesia (Narketan, Vetoquinol UK Ltd., 80 mg/kg b.w.;
Xylapan, Vetoquinol UK Ltd., 12 mg/kg b.w., intraperitoneal)
following whole blood and tissue collection. The blood was
collected by intracardiac puncture into a heparinised tube and
the plasma was separated by centrifugation. The kidneys, liver,
and brain were carefully removed and washed in ice-cold saline.
Each tissue (1 g) was homogenised in 10 mL of PBS (0.05 M,
pH 7.4) containing 0.1 mM of EDTA using a motor-driven
homogenizer. Both WB and BP were diluted to 10% with PBS.
AgNO3, PVP-AgNP, AOT-AgNP, and PLL-AgNP were mixed
at a concentration of 100 mg Ag/L with 1% of WB, BP, and
tissue homogenates for 30 min on a digital waving rotator
(Thermo Scientific, USA). After incubation, the samples were
diluted 1:5 with PBS, dropped on a Formvar®-coated TEM
grid, air-dried, and examined by TEM (PBS was used as
control).
In addition, liver tissues obtained from animals treated with
PVP-AgNPs were prepared for TEM examination. The speci-
mens were fixed in 2.5% glutaraldehyde in 0.1 M of PB, pH
7.4. After rinsing in the same buffer, the specimens were post-
fixed in 2% osmium tetroxide in the same buffer for 30 min. All
the specimens were then dehydrated in a series of graded alco-
hols, and embedded in TAAB embedding resin (TAAB, Alder-
maston, UK). After sectioning on a Leica UC6 ultramicrotome
(Leica Microsystems, Vienna, Austria) using a Diatome
diamond knife (Ultra 45; Diatome, Biel, Switzerland), they
were contrasted using uranyl acetate and lead citrate. The TEM
images were made in a microscope (902A; Carl Zeiss Meditec
AG, Jena, Germany) operating in bright-field mode with an
acceleration voltage of 80 kV and a Canon PowerShot S50
camera was used to capture the images.
All experiments were performed following the animal welfare
international standards and national legislation and were
approved by the Animal Care Committee and Ethical
Committee of the Institute for Medical Research and Occupa-
tional Health.
Stability evaluation of AgNPs in artificial
biological media
The behaviour and transformations of AgNPs were assessed
after the exposure to different biological media (PB, PBS,
CCM, m(CCM+BSA), mCYS, m(CYS+BSA), mGSH,
m(GSH+BSA), ALF, and AGF), as well as in WB, BP, and
10% (v/v) homogenates of rat tissues (liver, brain, kidney) of
male rats. The exact composition and parameters of each medi-
um are listed in Table 1. The preparation of ALF followed a
protocol published elsewhere [62] and included a pH adjust-
ment to 4.5 with NaOH solution.
The stock suspensions of AgNPs (1000 mg Ag/L) in UPW were
diluted in each medium (see Table 1) to a final AgNP concen-
tration of 10 mg Ag/L and incubated at room temperature on a
digital waving rotator (Thermo Scientific, USA), protected from
light. The changes in size distribution and zeta potential were
monitored by DLS and ELS, respectively, with the recordings
taken at 0, 1, 4, and 24 h after mixing. Additionally, UV–vis
spectra of all AgNPs suspensions in UPW and different biologi-
cal media were recorded on a CARY 300 spectrophotometer
(Varian Inc., Australia) following the same conditions. The
UV–vis measurements were performed in a quartz cuvette
with an optical path of 1 cm, in the wavelength range of
200–700 nm.
The dissolution behaviour of AgNPs was tracked in UPW,
CCM, m(CCM+BSA), mCYS, m(CYS+BSA), mGSH,
m(GSH+BSA), ALF, and AGF after 0, 1, 4, and of 24 h of
incubation. Briefly, stock suspensions of AgNPs were diluted in
the tested media to a final concentration of 10 mg Ag/L and
kept in the dark at room temperature. A sample was taken
immediately after dilution (0 h) and subsequently after 1, 4, and
24 h. The samples were processed by ultrafiltration using
Amicon-4 Ultra centrifugal filter units with a cut-off size of
3 kDa (Merck Millipore, Darmstadt, Germany) in order to sepa-
rate the dissolved silver from the AgNPs. The filtrates were
immediately acidified with Suprapur HNO3 to final acid content
of 10% (v/v). The quantification of dissolved Ag in the filtrates
was performed by GFAAS (Perkin Elmer AAnalyst 600, Perkin
Elmer, Shelton, USA) with Zeeman background correction. The
results are presented as % of the dissolved Ag fraction com-
pared to the total Ag content in AgNP suspensions before filtra-
tion.
Transmission electron microscopy was performed for different
AgNPs dispersed in PBS, mCYS, and mGSH media at a con-
centration of 10 mg Ag/L after 30 min of incubation. The sam-
Beilstein J. Nanotechnol. 2021, 12, 665–679.
677
ples were diluted 1:5 with PBS, dropped on a Formvar®-coated
copper grid, air-dried, and examined by TEM. The TEM visual-
ization was also employed to inspect possible transformation of
ionic Ag to AgNP in mCYS and mGSH media by dissolving
AgNO3 in each media at a concentration of 100 mg Ag/L. After
2 h of incubation at room temperature, 10 μL of the reaction
mixture aliquot was dropped on a TEM grid, air-dried, and ex-
amined by TEM. The images were taken using a 300 kV trans-
mission electron microscope FEI Tecnai F30 (FEI Company,
The Netherlands) equipped with a high angle annular dark field
(HAADF) detector and enabled to work in scanning transmis-
sion (STEM) mode to perform EDX analysis.
NMR experiments
As the incubation of ionic Ag in mGSH media showed the ap-
pearance of AgNPs (observed both visually and by TEM), the
interaction between AgNO3 and GSH was evaluated by NMR
spectroscopy. The spectra of free GSH (5 mM) and a mixture
containing 5 mM of GSH and 10 mM of AgNO3 in PB after 2 h
of incubation at 25 °C were obtained. The samples were pre-
pared with the addition of D2O to a final concentration of
10% (v/v). The 1H NMR spectra were recorded on a Varian
INOVA 400 spectrophotometer (Varian, PaloAlto, CA, USA)
operating at 399.6 MHz. The chemical shifts were expressed in
parts per million (ppm), referenced to the residual water signal.
All spectra were recorded at 25 °C. The signal of the solvent
was suppressed by using the PRESAT pulse sequence, avail-
able in the VnmrJ (4.2A) software.
Supporting Information
This file shows three tables with values of hydrodynamic
diameter, % volume distribution, zeta potential, and % of
dissolved AgNPs immersed in different media.
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